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The protein C anticoagulant pathway is essential for
normal haemostasis, downregulating thrombin genera-
tion after the coagulation cascade has been activated
[1,2]. When thrombin binds to the endothelial cell
transmembrane protein thrombomodulin, its potent
procoagulant functions are reversed, and its substrate
specificity is redirected towards protein C, which it
activates. This key step is enhanced by a second endo-
thelial cell transmembrane protein, the endothelial cell
protein C receptor (EPCR) [3–5], which concentrates
protein C on the endothelial cell surface, reducing the
Km for protein C activation by the thrombin-thrombo-
modulin complex [6]. Activated protein C (APC) exerts
its anticoagulant activity by inactivating factors Va
(FVa) and VIIIa by limited proteolysis, thereby
attenuating thrombin generation [7–9]. APC-mediated
inactivation of FVa involves the cleavage of peptide
bonds at positions Arg306, Arg506 and Arg679 of FVa
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Uniquely amongst vitamin K-dependent coagulation proteins, protein C
interacts via its Gla domain both with a receptor, the endothelial cell
protein C receptor (EPCR), and with phospholipids. We have studied
naturally occurring and recombinant protein C Gla domain variants for
soluble (s)EPCR binding, cell surface activation to activated protein C
(APC) by the thrombin–thrombomodulin complex, and phospholipid
dependent factor Va (FVa) inactivation by APC, to establish if these
functions are concordant. Wild-type protein C binding to sEPCR was
characterized with surface plasmon resonance to have an association
rate constant of 5.23 · 105 m)1Æs)1, a dissociation rate constant of
7.61 · 10)2 s)1 and equilibrium binding constant (KD) of 147 nm. It was
activated by thrombin over endothelial cells with a Km of 213 nm and
once activated to APC, rapidly inactivated FVa. Each of these interac-
tions was dramatically reduced for variants causing gross Gla domain
misfolding (R-1L, R-1C, E16D and E26K). Recombinant variants Q32A,
V34A and D35A had essentially normal functions. However, R9H and
H10Q ⁄S11G ⁄S12N ⁄D23S ⁄Q32E ⁄N33D ⁄H44Y (QGNSEDY) variants had
slightly reduced (< twofold) binding to sEPCR, arising from an increased
rate of dissociation, and increased Km (358 nm for QGNSEDY) for
endothelial cell surface activation by thrombin. Interestingly, these vari-
ants had greatly reduced (R9H) or greatly enhanced (QGNSEDY) ability
to inactivate FVa. Therefore, protein C binding to sEPCR and phospho-
lipids is broadly dependent on correct Gla domain folding, but can be
selectively influenced by judicious mutation.
Abbreviations
APC, activated protein C; FVa, factor Va; sEPCR, soluble endothelial cell protein C receptor; SPR, surface plasmon resonance.
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[10,11]. Cleavage at Arg506 occurs approximately 20-
fold faster than cleavage at Arg306 [12], and this step is
greatly accelerated by the presence of anionic phos-
pholipids [13]. The cleavage at Arg679 (the slowest of
the three cleavage steps) is of uncertain functional sig-
nificance, but may contribute to the inactivation of two
naturally occurring FV variants, FV Cambridge and
FV Hong Kong [14]. APC also activates protease-
activated receptor 1 (PAR1) [15], and has been shown
to protect brain endothelial cells from p53-mediated
apoptosis in an EPCR-dependent manner [16].
Cell surface full-length EPCR (residues 1–221,
mature protein numbering) and truncated EPCR (sol-
uble or sEPCR, residues 1–193) bind protein C and
APC with equal affinity [17–19]. The interaction of
protein C with EPCR ⁄ sEPCR is dependent upon Ca2+
ions [3,18]. The Gla domain of protein C, through
which the interaction with EPCR takes place, is the
source of this Ca2+ dependence [20]. The Gla domain
contains post-translationally c-carboxylated Glu resi-
dues and undergoes a large structural transition in the
presence of physiological concentrations of Ca2+ ions
[21–23]. A critical step in the structural transition is
the formation of the x-loop (approximately residues
1–11) [24,25]. This endows protein C, and other vita-
min K-dependent proteins, with the ability to bind
anionic phospholipid surfaces [16,26,27] and is there-
fore crucial for its activity.
The crystal structures of recombinant sEPCR, and
sEPCR in complex with the Gla domain of protein C,
have recently been solved [25]. As predicted [18,28–30],
the overall fold of sEPCR is similar to that of the
CD1 ⁄MHC class I family of proteins, consisting of a
b-pleated sheet platform supporting two a-helices. A
tightly bound phospholipid moiety was found to reside
in the groove between the two a-helices of the EPCR.
Although it does not seem to interact with protein C
directly, the phospholipid moiety appears to be
required for protein C binding to EPCR [25]. A small
clustered patch of residues on the EPCR, which
include residues on both a-helices, was found to inter-
act with protein C [31]. These residues were positioned
to interact with the Gla domain of protein C, specific-
ally the x-loop.
Information on the functional consequences of resi-
due substitution in the protein C Gla domain has
come from two sources. Firstly, protein C deficiency is
a known risk factor for venous thrombosis and the
mutational analysis of this deficiency has identified
causative amino acid substitutions [32]. Type II (func-
tional) deficiency is associated with normal protein C
antigen levels but reduced activity. Type II clotting
deficiency is diagnosed when the amidolytic activity
with respect to synthetic substrates is normal, but the
anticoagulant activity is reduced. In the latest pub-
lished update of the protein C deficiency database, of
the 335 mutations (161 unique events) that have been
identified in patients in association with protein C defi-
ciency, at least 30 are associated with type II clotting
deficiency and 14 of these are located in the Gla
domain [32]. Secondly, more detailed structure–func-
tion relationships have been identified by in vitro muta-
genesis and expression of recombinant protein C
variants. Using this approach, loss- and gain-of-func-
tion variants have been characterized [33–39].
Most investigations of the functional properties of
protein C Gla domain variants have focused upon
APC interaction with anionic phospholipids and the
subsequent effect on FVa inactivation; that is the
anticoagulant function of the enzyme. Before this
anticoagulant function can be expressed, however,
protein C must first be activated on the endothelial cell
surface. Activation involves protein C interaction with
EPCR and presentation of EPCR-bound protein C to
the thrombin–thrombomodulin complex for proteolysis
of its activation peptide. In this report, we examine
how binding to EPCR is influenced by protein C Gla
domain mutation, with particular reference to natur-
ally occurring protein C Gla domain variants associ-
ated with type II clotting deficiency. We also provide
the first evidence that the EPCR and membrane bind-
ing properties of protein C can be selectively influ-
enced by specific mutation.
Results
Expression and characterization of recombinant
EPCR
Recombinant wild-type sEPCR was prepared using the
yeast Pichia pastoris expression system. In addition to
binding protein C with expected affinity (see below),
the wild-type sEPCR was also able to inhibit the anti-
coagulant activity of APC in a modified clotting assay,
as described previously [1 40]. Using SDS ⁄PAGE and
Western blot analysis with the rat monoclonal RCR-2,
sEPCR was found to be heterogeneous, probably due
to N-linked glycosylation. Indeed, treatment of sEPCR
with PNGase F resulted in increased mobility and the
smeared bands resolved into a single defined band
(data not shown). Variant forms of sEPCR were gen-
erated by site-directed mutagenesis (N30Q, L37A and
E86A) and were expressed, concentrated and buffer-
exchanged using gel filtration. These mutants migrated
with similar mobility to that of wild-type sEPCR on
SDS ⁄PAGE, except for variant N30Q that had slightly
Interaction of protein C with EPCR and phospholipids R. J. S. Preston et al.
98 FEBS Journal 272 (2005) 97–108 ª 2004 FEBS
increased mobility attributed to the removal of a pre-
dicted carbohydrate side chain.
Expression and characterization of protein C Gla
domain variants
Two natural protein C variants, R-1L and R-1C, were
selected for study and the variant component isolated
from plasma. Two other naturally occurring protein C
variants, R9H and E26K, were expressed using
HEK293 cells. Protein C variants with point mutations
(E16D, Q32A, V34A and D35A) were also generated.
Finally, a variant with multiple residue substitu-
tions, H10Q ⁄S11G ⁄S12N ⁄D23S ⁄Q32E ⁄N33D ⁄H44Y
(QGNSEDY), reported previously to exhibit enhanced
anionic phospholipid affinity and increased anticoagu-
lant activity [37], was also studied. Recombinant vari-
ants were expressed at concentrations ranging between
0.9 and 7 lgÆmL)1 and migrated as closely spaced
62 kDa doublets under nonreducing conditions (data
not shown), in accordance with previous reports
[36,37,41,42]. Expressed protein C was subsequently
concentrated and partially ⁄ fully purified from condi-
tioned medium by ion-exchange chromatography. To
ensure that the catalytic site of each variant was func-
tional, they were activated by the human protein C
carrier, Protac2 , and their amidolytic properties evalu-
ated. The wild-type and variant preparations could all
be fully activated by Protac and efficiently cleaved the
chromogenic substrate S-2366, with Km and kcat
parameters comparable to those for wild-type APC
described in the literature [43] (data not shown).
Activation of protein C Gla domain variants
on the surface of endothelial cells
To investigate the activation of protein C variants by
the thrombin–thrombomodulin complex in the pres-
ence of EPCR, each variant was activated by thrombin
over the surface of an endothelial cell line3 , EA.hy926.
The activation of recombinant wild-type protein C was
characterized by a Km of 213 ± 42 nm (Fig. 1 and
Table 1), similar to the Km for plasma protein C acti-
vation (155 nm; data not shown) and similar to previ-
ously reported values [4].
The activation of variants E16D and E26K by
thrombin on EA.hy926 cells at concentrations up to
1 lm was barely detectable (Fig. 1A and Table 1).
However, small amounts of protein C could be activa-
ted on the surface of endothelial cells at concentrations
higher than 1 lm, suggesting some activation by the
thrombin–thrombomodulin complex had taken place
(data not shown).
The Km values for activation of variants R9H,
Q32A, V34A, D35A and QGNSEDY on the cell sur-
face were normal or slightly increased (Fig. 1 and
Table 1). Activation of QGNSEDY and R9H variants
was also characterized by slight increases in the Vmax
for this reaction, with the increase for QGNSEDY
being approximately twofold (Fig. 1A, Table 1). To
further investigate this, the activation of QGNSEDY
by thrombin on the surface of cells expressing throm-
bomodulin alone was determined. Interestingly, over
the surface of HEK293-TM cells, the Km for activation
of wild-type protein C and QGNSEDY by thrombin
were closely comparable (Km ¼ 666 ± 182 nm and
Fig. 1. Activation of protein C Gla domain variants on EA.hy926
cells. EA.hy926 cells were grown in triplicate to confluence in the
wells of a 96-well plate and washed as described in Experimental
procedures. Recombinant protein C was added to the wells in a
range of concentrations (12.5–1000 nM) in HBSS containing 3 mM
CaCl2 and 0.6 mM MgCl2 and activation initiated by the addition of
13.5 nM thrombin. After 30 min, the thrombin was inhibited with a
10-fold excess of hirudin (135 nM) and the APC formed detected
with the chromogenic substrate S-2366 (see text). (A) Protein C
variants R9H (e); E16D (n); E26K (j); QGNSEDY (r). (B) Q32A
(m); V34A (n); D35A (r). Wild-type protein C (s) in both panels.
Results are presented as the mean ± SD of three individual experi-
ments.
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603 ± 112 nm, n ¼ 3), respectively, with no difference
in Vmax. This indicated that the increased Vmax was
dependent upon cell-surface EPCR.
Affinity of protein C Gla domain variants
for sEPCR
Surface plasmon resonance (SPR) was used to analyse
the binding kinetics of each protein C variant for sEP-
CR. sEPCR has been previously reported to lose activ-
ity when bound directly to artificial surfaces [4].
Therefore, the anti-EPCR monoclonal antibody, RCR-
2, was first immobilized onto the surface of a CM5 sen-
sor chip, and sEPCR captured onto one of the two flow
cells of the sensor chip. To investigate the nature of
RCR-2 binding to sEPCR, recombinant wild-type sEP-
CR and several sEPCR variants were expressed and
their concentrations and binding to RCR-2 determined
by SPR. Wild-type sEPCR bound to RCR-2 with an
association rate, ka, of 5.39 ± 0.97 · 104 m)1Æs)1 and
dissociated with a kd of 3.28 ± 0.58 · 10)4Æs)1. The
equilibrium constant (KD) was 6.1 ± 0.1 nm (Fig. 2A
and Table 2). Similar results were obtained with variant
sEPCR with the substitution E86A. Glu86 is an
important residue of the protein C binding site on
EPCR [25,31]. In contrast, sEPCR with substitutions
N30Q and L37A had an impaired interaction, with
the kd for N30Q being particularly increased ( four-
fold) to 1.15 ± 0.04 · 10)3 s)1 (Fig. 2B and Table 2).
The KD for this variant was also increased to
16.3 ± 1.4 nm. These results demonstrate a slow off
rate (kd) for the interaction between wild-type sEPCR
and RCR-2 and furthermore suggest that the epitope
for RCR-2 on sEPCR is on the face of sEPCR oppos-
ite to its known binding site for protein C. The stability
of immobilized RCR-2 as a capture ligand for sEPCR
and protein C is illustrated in Fig. 2C. This shows ini-
tial binding of sEPCR to RCR-2 (Fig. 2C; panel 1), the
addition of increasing concentrations of protein C –
showing association, dissociation and regeneration
experiments – (Fig. 2C; panel 2) and final regeneration
of the RCR-2 immobilized chip by injection of 10 mm
glycine ⁄HCl (Fig. 2C; panel 3).
The binding of protein C to sEPCR was initially
characterized using wild-type and variant forms of sEP-
CR. Human plasma protein C associated with RCR-2
immobilized wild-type sEPCR in a concentration-
dependent manner (Fig. 3A). The association and dis-
sociation rate constants were 12.1 ± 1.29 · 105 m)1Æs)1
and 8.96 ± 1.09 · 10)2 s)1, yielding a calculated KD of
74.8 ± 9.2 nm. Binding of plasma protein C was com-
pletely abolished when sEPCR with the substitution
E86A was used (Fig. 3B).
Recombinant wild-type protein C bound to sEPCR
with a KD ¼ 147 ± 23 nm (Table 3), somewhat higher
than the value derived for plasma protein C. This was
caused by a lower ka for recombinant protein C
(5.23 ± 0.74 · 105 m)1Æs)1) (Table 3) compared with
plasma protein C (12.1 ± 1.29 · 105 m)1Æs)1). The two
protein C Gla domain variants sourced from human
plasma, those containing R-1C and R-1L substitutions,
exhibited no binding to sEPCR (Table 3). Also, no
detectable binding for variants E16D and E26K to
sEPCR was observed at concentrations up to 200 nm
(Table 3). Protein C variants R9H, Q32A, V34A,
D35A, and QGNSEDY variants had readily detectable
binding to sEPCR, but all exhibited slightly reduced
affinities compared to recombinant wild-type protein C
(Table 3). Repeated analyses also suggested slightly
faster dissociation rates (approximately twofold) for
the R9H and QGNSEDY variants compared to
recombinant wild-type protein C, which may have con-
tributed to the increased KD values of 256 ± 96 and
216 ± 53 nm, respectively (Table 3).
Inactivation of FVa by APC Gla domain variants
The inactivation of FVa on phospholipids by APC is
strongly dependent on APC binding to anionic phos-
pholipids. Therefore, to indirectly assess APC variant
affinity for phospholipids, FVa inactivation by each
recombinant variant was determined. FVa inactivation
by recombinant wild-type APC was characteristically
biphasic, with rate constants of 4.63 · 107 m)1Æs)1 and
5.51 · 106 m)1Æs)1 for cleavage of FVa at Arg506 and
Arg306, respectively, in agreement with previously
Table 1. Activation of protein C Gla domain variants on EA.hy926
cells. Km values were derived by fitting data derived from the acti-
vation of protein C on the surface of EA.hy926 cells with thrombin
(Fig. 1) to the Michaelis–Menten equation. Km values were
obtained for each variant, and represent the mean ± SD of a mini-
mum of three independent experiments, except R-1L and R-1C,
where n ¼ 2 due to limited material isolated from plasma. ND, not
detectable.
Protein C Km (nM) Vmax (nMÆmin
)1)
Wildtype protein C 213 ± 42 2.35 ± 0.16
R-1C ND ND
R-1L ND ND
R9H 224 ± 18 3.15 ± 0.10
E16D ND ND
E26K ND ND
Q32A 188 ± 28 2.03 ± 0.18
V34A 236 ± 80 2.37 ± 0.08
D35A 123 ± 8 2.27 ± 0.09
QGNSEDY 358 ± 76 4.99 ± 0.34
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defined values [12,44]. The fitted inactivation data
(Fig. 4B) and the kinetic rate constants for FVa inacti-
vation by Q32A, V34A and D35A APC variants were
virtually identical to those described for wild-type
APC (data not shown). Under our experimental condi-
tions, the severely reduced rates of FVa inactivation
by R9H, E16D and E26K APC variants (Fig. 4A)
meant that accurate kinetic rate constants for individ-
ual FVa cleavages using the biphasic model could not
be derived. As such information was of limited value
in view of the severely reduced extent of total inactiva-
tion (Fig. 4A) it was not pursued further. In contrast,
the activated QGNSEDY variant demonstrated a
markedly increased ability to inactivate FVa compared
to wild-type APC (Fig. 4A), with the Arg306 cleavage
being mainly (2.53-fold) affected.
Table 2. Kinetic parameters of the binding of sEPCR and its vari-
ants to the monoclonal antibody RCR)2. Interaction of wildtype
and variant sEPCR with substitution mutations N30Q, L37A and
E86A with mAb RCR-2 as assessed by SPR (see Fig. 2). The
association rate constants (ka), dissociation rate constants (kd) and
the equilibrium dissociation constants (KD ¼ kd ⁄ ka) were derived
from the SPR data using Biacore software (BIAEVALUATION 3.0). Data
sets were fit to the 1 : 1 Langmuir model (see Experimental proce-
dures). Rate constants are presented as the mean value of (n ¼ 2–
4) independent experiments ± SD.
sEPCR
ligand ka (M
)1Æs)1) kd (s
)1) KD (nM)
Wildtype (5.39 ± 0.97) · 104 (3.28 ± 0.58) · 10)4 6.1 ± 0.1
N30Q (7.04 ± 0.37) · 104 (1.15 ± 0.04) · 10)3 16.3 ± 1.4
L37A (7.78 ± 0.26) · 104 (6.45 ± 0.78) · 10)4 8.3 ± 0.4
E86A (6.32 ± 0.83) · 104 (3.51 ± 0.20) · 10)4 5.6 ± 0.3
Fig. 2. SPR analysis of binding between sEPCR and protein C using
the capture mAb RCR-2. (A) Binding of wild-type sEPCR to RCR-2.
Approximately 200 ng mAb RCR-2 was immobilized on one flow
cell of a CM5 sensor chip, giving a corrected response of 2000 RU
(see Experimental procedures). A nonreactive mAb was used as a
control for nonspecific binding in the reference flow cell. Increasing
concentrations of wild-type sEPCR (13–106 nM) were injected
across both flow cells. The association of sEPCR with RCR-2 was
assessed for 5 min at a flow rate of 20 lLÆmin)1. (B) Binding of
sEPCR N30Q to RCR-2. The amount of immobilized RCR-2 corres-
ponded to 1500 RU. The experiment was otherwise performed
under identical conditions to A using sEPCR variant N30Q instead
of wild-type sEPCR (concentration range 7.2–115 nM). (C) Complete
EPCR ⁄ protein C binding cycle. 1, Wildtype sEPCR (800 ng) was
injected across the flow cell of a CM5 sensor chip coated with
RCR-2. sEPCR was injected for 2 min at a flow rate of 10 lLÆmin)1
and equilibrated for 10 min. 2, Increasing concentrations of plasma
protein C (18–133 nM) were injected across the RCR-2–sEPCR
complex, for 80 s at 30 lLÆmin)1. Dissociation of protein C from
sEPCR was achieved by injection of HBS-EP buffer, containing
3 mM EDTA. 3, Injection of 10 mM glycine ⁄HCl pH 2.5 regenerated
the antibody surface by the complete removal of sEPCR from the
CM5 chip surface. The data shown in the figure are representative
sensograms for each set of experiments.
Fig. 3. Interaction of plasma protein C with sEPCR. RCR-2 was
used to capture sEPCR on a CM5 sensor chip (see Experimental
procedures for details). RCR-2 (300 ng) was injected onto the sen-
sor surface and gave a response of 3600 RU. (Upper) Binding of
protein C to wild-type sEPCR. Approximately 400 RU of sEPCR
was captured before sequential injections containing decreasing
concentrations of protein C (concentration range 18–200 nM).
(Lower) Lack of protein C binding sEPCR with substitution E86A.
The response level of this variant was 540 RU prior to sequential
injections containing decreasing concentrations of protein C (range
54–300 nM).
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Discussion
Vitamin K-dependent proteins interact through their
characteristic Gla domains with phospholipid mem-
brane surfaces. The Gla domains exhibit appreciable
amino acid sequence similarity. When Ca2+ is bound,
the Gla domain folds into a conserved x-loop exposing
surface-orientated hydrophobic residues that are pro-
posed to make membrane contact [26]. The membrane
binding properties of vitamin K-dependent proteins is
facilitated by the presence of phosphatidylserine.
Recent analysis of the prothrombin Gla domain com-
plexed with lysophosphatidylserine identified inter-
actions of the serine head group with bound Ca2+
ions, Gla17 and Gla21. Extensive interactions were
also detected between lysophosphatidylserine and resi-
dues of the x-loop, including Phe5, Leu6 and Gla7.
Furthermore, the glycerophosphate backbone was
shown to interact with a basic region of the Gla
domain containing Lys3, Arg10 and Arg16 [27]. Con-
sequently, a general model of Gla domain membrane
contact has been proposed that involves both hydro-
phobic and ionic interactions. Such a model is compat-
ible with experimental data showing the limited effects
of targeted mutagenesis on Gla domain binding to
membranes [33].
Of the coagulation proteins, protein C is unique in
binding EPCR with high affinity. This interaction is
mediated by the protein C Gla domain. According to
a recent crystal structure [25], the majority of pro-
tein C residues contributing to the EPCR interaction
are located on the x-loop. One direct pivotal contact
was shown to be made between the Ca2+ ions bound
to the protein C Gla domain and the EPCR (Glu86 of
EPCR). All remaining contacts (hydrogen bonds
and ⁄or hydrophobic interactions) were directly
between residues of the protein C Gla domain (Phe4,
Gla7, Leu8, Gla25 and Gla29) and EPCR (Leu82,
Table 3. Interaction of protein C Gla domain variants with recom-
binant wildtype sEPCR. Affinity of protein C Gla domain variants for
sEPCR was assessed using SPR. The association rate constants
(ka), dissociation rate constants (kd) and equilibrium dissociation rate
constants (KD) were derived as described in Experimental proce-
dures using the 1 : 1 binding with drifting baseline model. Associ-
ation and dissociation rates and equilibrium binding constants are
presented as the mean of three independent experiments ± stand-
ard deviation.
Protein C ka (M
)1Æs)1) kd (s
)1) KD (nM)
Wildtype
protein C
(5.23 ± 0.74) · 105 (7.61 ± 0.45) · 10)2 147 ± 23
R-1C No binding No binding No binding
R-1 L No binding No binding No binding
R9H (5.40 ± 2.96) · 105 (11.4 ± 0.96) · 10)2 256 ± 96
E16D No binding No binding No binding
E26K No binding No binding No binding
Q32A (2.86 ± 0.58) · 105 (9.98 ± 0.21) · 10)2 259 ± 74
V34A (5.29 ± 1.47) · 105 (9.80 ± 1.56) · 10)2 176 ± 39
D35A (4.31 ± 1.55) · 105 (8.42 ± 0.51) · 10)2 217 ± 93
QGNSEDY (6.07 ± 1.93) · 105 (12.8 ± 0.58) · 10)2 216 ± 53
Fig. 4. Inactivation of FVa by APC Gla domain variants. FVa (4 nM)
was incubated with 75 lM phospholipid vesicles containing phos-
phatidylcholine and phosphatidylserine (90 : 10, v ⁄ v) and 0.08 nM
APC in 40 mM Tris ⁄HCl, 140 mM NaCl, 3 mM CaCl2 and 0.3%
(w ⁄ v) BSA at 37 C. Aliquots (2 lL) were removed and added to
75 lM phospholipids (phosphatidylcholine and phosphatidylserine;
90 : 10, v ⁄ v), 3 nM factor Xa and 1.5 lM prothrombin at time points
between 0 and 20 min. Each reaction was stopped after three
minutes using 3 lL ice-cold 0.5 M EDTA. Loss of FVa activity was
also determined by fitting the curves using nonlinear regression
analysis (see Experimental procedures) to derive the kinetic param-
eters listed in [12]. (A) APC variants R9H (s); E16D (n); E26K (e);
QGNSEDY (j). (B) Q32A (h); V34A (n); D35A (s). wildtype APC
(r) and FVa only (d) are the same in both panels. Results are
expressed as the mean ± SD of three individual experiments.
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Arg87, Gln150, Tyr154 and Thr157). Consequently,
the structural features of protein C required for mem-
brane and EPCR interactions appear to be partially
shared.
In this study, the contributions of protein C Gla
domain residues to both of these interactions, and
their subsequent effect on anticoagulant activity, have
been examined. Nine plasma ⁄ recombinant protein C
variants were isolated or generated, and four of these
were selected because they are known to have impaired
anticoagulant activity. Each of the nine variants were
characterized by activation over the surface of endo-
thelial cells, their binding to recombinant sEPCR, and
by their abilities to inactivate FVa in a phospholipid-
dependent manner. Two of the variants (R-1L and
R-1C) were purified from the plasma of heterozygous
carriers. These variants are incorrectly processed by
the signal peptidase at their amino-terminal residues.
Furthermore, a proportion of the R-1C variant is
known to be present as heterodimers with a1-micro-
globulin [45]. Neither variant was able to bind to sEP-
CR or be efficiently activated by thrombin over the
endothelial cell surface. A further means of inhibition
of the Ca2+-induced conformational change of the
protein C Gla domain is the substitution of c-carbox-
ylated Glu residues. Two such substitutions arise in
the naturally occurring variant E26K [46,47] and the
engineered conservative substitution variant E16D.
They too are shown here to be unable to bind sEPCR
(Table 3), have negligible activation over the surface of
endothelial cells by the thrombin–thrombomodulin
complex (Table 1), and to have grossly impaired
abilities to inactivate FVa once activated to APC
(Fig. 4A).
As the natural and recombinant variants described
above have such abnormal binding and activation
properties, it was of interest to study other protein C
recombinant variants in the protein C Gla domain that
might be predicted to perturbate, but not fully disrupt,
Gla domain folding and functions. Three potentially
dysfunctional variants with substitutions Q32A, V34A
and D35A were chosen for investigation because of a
preliminary abstract report that suggested the binding
site for the EPCR on protein C was located between
residues 25 and 40 [48]. This report was based upon
the observation that a chimeric molecule with residues
1–22 of prothrombin and 22–45 of protein C bound
EPCR, whereas a protein C chimera with residues 1–
45 of prothrombin did not. We therefore selected three
residues on protein C that differed from the homolog-
ous prothrombin sequence [49] and generated variants
containing an alanine residue at each of these posi-
tions. In the event, the interactions of these variants
with sEPCR were essentially normal (Table 3), as was
their activation over the endothelial cell surface
(Table 1) and their ability to inactivate FVa once acti-
vated to APC (Fig. 4B).
The R9H variant, another example of a Gla
domain residue substitution causing a type II defici-
ency phenotype [50], displayed only a small reduction
in affinity for sEPCR and a similar Km for endothel-
ial cell activation by thrombin to that of wild-type
protein C (Tables 1 and 3). In contrast, the ability of
the R9H APC variant to fully inactivate FVa was
markedly compromised (Fig. 4) suggestive of an
impaired interaction with anionic phospholipids. The
R9H substitution may therefore selectively perturbate
protein C Gla domain function by reducing protein C
Gla domain affinity for phospholipids without sub-
stantially affecting interaction with EPCR. The
homologous residue in the bovine prothrombin Gla
domain, Arg10 is discussed above. Our results suggest
that Arg9 may form part of a similar basic region on
the protein C Gla domain surface for contact with
phosphatidylserine, and thereby contribute import-
antly to the protein C ⁄APC–phospholipid interaction.
Further evidence for selective modulation of pro-
tein C Gla function is provided from results of the
protein C variant QGNSEDY. This variant exhibited
near-normal sEPCR binding (a KD value of 216 nm
compared to 147 nm for wild-type protein C; Table 3),
which appears to be caused by an increased kd. The
Km and Vmax for activation of this variant on the
endothelial cell surface by the thrombin–thrombomod-
ulin complex were slightly increased (Table 1 and
Fig. 1). In contrast, the ability of QGNSEDY to inac-
tivate FVa in a phospholipid-dependent manner was
markedly enhanced (Fig. 4A), as has been reported
previously [37]. Because of the composite nature of the
QGNSEDY variant, it is currently uncertain how its
Gla domain has been selectively altered to enhance
phospholipid binding.
The results of this study highlight for the first time
the importance of natural protein C Gla domain muta-
tions in impairing protein C binding to EPCR and its
endothelial cell surface activation by the thrombin–
thrombomodulin complex. Carriers of certain pro-
tein C Gla domain mutations are known to be at
increased risk of thrombosis. It is highly plausible that
impaired cell surface protein C activation could con-
tribute to that risk. Protein C variants with gross mis-
folding of the Gla domain will have impaired cell
surface activation that will in part be determined by a
reduced interaction with EPCR. Patients with hetero-
zygous R-1L or R-1C mutations, in particular, have
been reported to present with a severe thrombotic
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manifestation. In such an instance, a deficiency of anti-
coagulant activity will arise from reduced APC activity
against FVa due to loss of phospholipid affinity, but
potentially also from an impaired rate of protein C
activation, an inevitable by-product of deficient EPCR
binding.
Recombinant APC is one of the few novel therapies
to be used successfully in the treatment of sepsis [51].
Its ability to reduce mortality appears due in part to
EPCR-bound APC proteolysis of PAR1 on the surface
of endothelial cells [15]. PAR1 cleavage by APC has
been shown to mediate signal transduction pathways
and contribute to APC antiapoptotic and neuroprotec-
tive activities [16,52]. This nonanticoagulant activity is
entirely reliant on the APC–EPCR interaction. Select-
ive perturbation of protein C ⁄APC Gla domain func-
tions therefore represents a potential means by which
the anticoagulant and nonanticoagulant functions of
APC can be altered for improved therapeutic interven-
tion in the future.
Experimental procedures
Expression and purification of sEPCR
sEPCR was expressed in Pichia pastoris strain X-33 using
the EasySelect Pichia expression kit (Invitrogen, Paisley,
UK) broadly as described [53]. SEPCR variants were gener-
ated using the QuikChange mutagenesis kit (Stratagene, La
Jolla, CA, USA).
Purification of variant protein C from plasma
of heterozygous carriers
The purification of variant protein C from the plasma of
patients who were heterozygous for the mutations R-1L
and R-1C has been described previously [45,54]. Briefly, the
method utilized two immunoaffinity columns directed
against protein C. The first column resulted in efficient
purification of protein C from other plasma components,
whereas the second separated normal from variant pro-
tein C. The characterization of these APC variants has also
been reported previously [45,54] and consequently details of
the purification and characterization will not be replicated
here. The activities of these variants were compared to
human plasma protein C from Enzyme Research Laborat-
ories (ERL, South Bend, IN, USA).
Vector construction and expression of
recombinant protein C
The full-length protein C cDNA was cloned into the
vector pRc ⁄CMV (Invitrogen, Paisley, UK)4 to generate
wild-type protein C. Site-directed mutagenesis was per-
formed by the Quikchange mutagenesis kit (Stratagene,
La Jolla, CA, USA)5 to generate protein C variants. The
oligonucleotide primers used to generate the protein C
variant constructs R9H, E16D, E26K, Q32A, V34A
and D35A are available upon request. Preparation of
the H10Q ⁄S11G ⁄S12N ⁄D23S ⁄Q32E ⁄N33D ⁄H44Y construct
has been described previously [37]. The expression of
recombinant protein C using picked colonies of stably
transfected HEK293 cells (European Collection of Cell
Cultures, Wiltshire, UK) has been described in detail else-
where [36,37]. Serum-free conditioned medium containing
protein C was dialysed overnight against 20 mm Tris ⁄HCl
(pH 7.4), 150 mm NaCl. Protein C was concentrated and
partially or fully purified by ion-exchange chromatography
in 20 mm Tris ⁄HCl, 150 mm NaCl (pH 7.4), using a Q
Sepharose Fast Flow column (Amersham Biosciences, Lit-
tle Chalfont, UK), with either a single step elution to 1 m
NaCl or elution with 3 mm CaCl2 [37]. Purified fractions
were dialysed overnight against Hanks Balanced Salt Solu-
tion (HBSS) before use. Expressed protein C has been
shown to have normal c-carboxylation [37].
Determination of protein C concentration
Protein C concentrations were determined either by absorb-
ance at 280 nm or by an ‘in-house’ ELISA. For the latter,
the method was similar to that previously described for the
determination of protein S concentration [55]. The only
modifications were the antibodies used. The capture anti-
body was the monoclonal antibody HC-2 (directed towards
the heavy chain of protein C) (Sigma-Aldrich, Poole, UK)
and the detection antibody was a horseradish peroxidase
(HRP)-conjugated polyclonal anti-protein C (Dako, Ely,
UK). SPR was used to confirm that the affinity of each
protein C variant for the capture antibody was identical,
and unaffected by Gla domain mutation. Standards (0.2–
7.8 lgÆmL)1) for the ELISA were prepared using purified
plasma protein C.
SDS ⁄PAGE and Western blotting
SDS ⁄PAGE and Western blotting were performed using
standard techniques. Briefly, for Western blot analysis,
protein C or sEPCR were loaded and separated by
SDS ⁄PAGE in a 4–20% (w ⁄ v) polyacrylamide Tris ⁄HCl
gel (Bio-Rad, Hemel Hempstead, UK)6 under nonreducing
or reducing conditions. Proteins in the gel were stained with
GelCODE Blue stain reagent (Pierce, Rockford, IL, USA).
Proteins transferred to Hybond–ECL (Amersham Bio-
sciences) were detected using either an HRP-conjugated
polyclonal anti-protein C or the anti-EPCR monoclonal
antibody RCR-2 followed by an HRP-conjugated goat
anti-(rat IgG) Ig (both from Dako).
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Determination of catalytic efficiency
of APC variants
Protein C was activated with Protac (Immuno, Heidelberg,
Germany) according to the method of Zhang and Castelli-
no [56]. Protein C at 5 lgÆmL)1 was incubated in 50 mm
Tris ⁄HCl (pH 7.4), 100 mm NaCl and 0.25 U Protac in a
total volume of 1 mL for 1 h at 37 C then 16 h at 4 C.
Steady-state substrate hydrolysis by each APC variant was
measured using an adapted method [57]. Essentially, 2 nm
of each APC variant was incubated with a range of concen-
trations of chromogenic substrate (S-2366; Chromogenix,
Milan, Italy) in 100 mm NaCl, 20 mm Tris ⁄HCl (TBS,
pH 7.5) containing 2.5 mm CaCl2, 0.1 mgÆmL
)1 BSA and
0.1% (v ⁄ v) polyethylene glycol (PEG 8000). The rate of
S-2366 hydrolysis was measured at 405 nm at room
temperature using an iEMS plate reader MF (Labsystems,
Basingstoke, UK). Curve fitting using the Michaelis–
Menten equation was performed using enzfitter software
(Biosoft, Cambridge, UK). The Km and kcat values were
derived from this equation.
Activation of protein c on endothelial cells
and HEK293-TM cells
EA.hy926 cells (the kind gift of C.-J. Edgell, University of
North Carolina, Chapel Hill, NC, USA) were used as they
express both EPCR [3,5] and thrombomodulin [58]. The
method of protein C activation was a modification of that
described by Suzuki et al. [59]. Cells were grown to conflu-
ence in 96-well plates and were washed using HBSS supple-
mented with 1% (w ⁄ v) BSA, 3 mm CaCl2, 0.6 mm MgCl2
and 0.1% (w ⁄ v) NaN3 (cHBSS–NaN3). Serial dilutions of
protein C (12.5–1000 nm) were prepared in cHBSS–NaN3
(ensuring a final concentration of 3 mm CaCl2 and 0.6 mm
MgCl2) and added to the wells. Activation was initiated by
the addition of purified human thrombin (ERL) (13.5 nm
final concentration) to each well and was allowed to pro-
ceed for 30 min at 37 C with gentle shaking. The reaction
was terminated by the addition of hirudin (Sigma) (135 nm
final concentration). Fifty microlitres of the resulting super-
natant was incubated with 50 lL of 2 mm S-2236 chromo-
genic substrate and the initial rate of increase in
absorbance at 405 nm was determined using an iEMS plate
reader MF. Generated APC was estimated using a standard
curve of purified APC. Curve fitting of the data to the
Michaelis–Menten equation was performed using enzfitter
software.
For activation of protein C on cells expressing thrombo-
modulin only, a similar assay was used, except that
HEK293 cells stably transfected with full-length thrombo-
modulin (HEK293–TM) were used. Briefly, HEK293–TM
cells were plated on a poly(l-lysine) (Sigma) coated 96-well
plate, and grown to confluence over a 24-h period. The cells
were washed gently, and protein C (25–3000 nm) in
cHBSS–NaN3 was added to the wells. Thrombin (13.5 nm
final concentration) was added to each well, and the plate
was then incubated for 30 min at 37 C with gentle sha-
king. The reaction was stopped with hirudin (135 nm final
concentration). Generation of APC was assessed using the
chromogenic substrate S-2366 as above.
Assessment of protein C–sEPCR interaction
by surface plasmon resonance (SPR)
All binding experiments were assessed by SPR using a dual
flowcell BIAcore X biosensor system (BIAcore, AB, Upp-
sala, Sweden). To determine the concentration of sEPCR,
an anti-EPCR monoclonal antibody (RCR-2) was covalen-
tly immobilized on a carboxymethylated dextran (CM5)
sensor chip (BIAcore) using amine coupling chemistry,
according to the manufacturer’s instructions. A single time
point on the association phase of wild-type sEPCR binding
in triplicate was used to generate a calibration curve for
sEPCR binding, the linear range of which was between 12.5
and 200 ngÆmL)1.
To characterize sEPCR binding to RCR-2, immobiliza-
tion was performed by injecting 200 ng RCR-2 across the
sensor chip surface at a flow rate of 5 lLÆmin)1. A response
in resonance units (RU) of between 1500 and 4000 was
established. A nonreactive mouse IgG was immobilized on
the reference flow cell and used to control for nonspecific
binding. Wild-type and variant forms of sEPCR (7.0–
115 nm) were prepared in 50 mm Hepes pH 7.4, 150 mm
NaCl (HBS-P, BIAcore) and sequentially injected over the
RCR-2 surface at a flow rate of 20 lLÆmin)1 with 5 min
contact time. The sensor chip surface was regenerated with
10 mm glycine ⁄HCl, pH 2.5.
To investigate protein C binding to sEPCR, protein C
and concentrated sEPCR samples were buffer-exchanged
into HBS-P with 3 mm CaCl2, 0.6 mm MgCl2 by gel filtra-
tion. RCR-2 (300 ng) was injected for 6 min across both
flow cells of a CM5 chip, generating a response of 3000–
6000 RU. sEPCR in HBS-P, containing 3 mm CaCl2
and 0.6 mm MgCl2, was injected and equilibrated at
10 lLÆmin)1 across one flow cell surface only providing an
approximately equal amount ( 500RU) of sEPCR bound
to RCR-2 for each experiment. Protein C concentrations
(0–200 nm) were sequentially injected over both flow cells
at a flow rate of 30 lLÆmin)1 for 80 s. The flow cell with-
out sEPCR bound was used as a reference cell. Any influ-
ence of mass transport effects was discounted from results
of binding and dissociation at different flow rates. A buf-
fer with 50 mm Hepes pH 7.4, 150 mm NaCl, 3 mm
EDTA (HBS-EP, BIAcore), was used to dissociate the
protein C–sEPCR complex. After each set of experiments,
the RCR-2 surface was regenerated with 10 mm gly-
cine ⁄HCl pH 2.5.
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Kinetic analysis of protein C binding to sEPCR
Data analysis was performed using the biaevaluation soft-
ware 3.0 (BIAcore). The association and dissociation phases
of all sensograms were fitted globally. Kinetics of wild-type
and variant forms of sEPCR binding to RCR-2 were deter-
mined using a 1 : 1 Langmuir binding model. Protein C
binding to sEPCR was fitted to a 1 : 1 baseline drift linear
model.
Phospholipid vesicle preparation
A phospholipid mixture containing dioleoyl-phosphatidyl-
choline and dioleoyl-phosphatidylserine (90 : 10, v ⁄ v) in
chloroform (Avanti Polar Lipids Inc, Alabaster, AL, USA)
was prepared, and the chloroform evaporated under nitro-
gen vapour. The phospholipids were resuspended in ice-cold
sterile water then mixed vigorously for 1 h with shaking at
4 C. Unilamellar phospholipid vesicles were prepared by
extrusion. The resuspended vesicles were passed 19 times
through a 0.1 lm membrane, then a further 19 times
through a 0.03 lm membrane using an Avanti Mini-Extru-
der (Avanti Polar Lipids Inc).
Determination of APC-mediated factor Va
inactivation
To determine FVa degradation by APC, 0.08 nm APC
was incubated with 75 lm of the above phospholipid vesi-
cles and 4 nm FVa (Haematologic Technologies Inc, VT,
USA) in 40 mm Tris ⁄HCl, 140 mm NaCl, 3 mm CaCl2
and 0.3% (w ⁄ v) BSA (0.02 nm APC, 19 lm phospholipids
and 1 nm FVa; final concentration). The mixture was incu-
bated at 37 C, and 2 lL aliquots removed and added to
a prothrombinase mixture, consisting of 75 lm phospholi-
pids (phosphatidylcholine and phosphatidylserine; 90 : 10,
v ⁄ v), 3 nm factor Xa and 1.5 lm prothrombin (Haemato-
logic Technologies Inc) (25 lm phospholipids, 1 nm factor
Xa and 0.5 lm prothrombin; final concentration) at
defined time points between 0 and 20 min. Each reaction
was stopped after three minutes using 3 lL ice-cold 0.5 m
EDTA. One-hundred microlitres of the reaction mixture
was then removed and incubated with 50 lL of chromo-
genic substrate S-2238 to assess thrombin generation,
as the rate of thrombin generation was proportional to
FVa activity. Calculation of kinetic rate constants for
cleavage at Arg506 and Arg306 of FVa by APC was
achieved using a model described previously for this
purpose [12].
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